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Summary
Drug resistance in lymphoblastic and myeloblastic
leukemia cells is poorly understood, with several lines
of evidence suggesting that resistance can be corre-
lated with upregulation of human asparagine synthe-
tase (hASNS) expression, although this hypothesis
is controversial. New tools are needed to investigate
this clinically important question, including potent
hASNS inhibitors. In vitro experiments showan adeny-
lated sulfoximine to be a slow-onset, tight-binding
inhibitor of hASNS with nanomolar affinity. This bind-
ing affinity represents a 10-fold improvement over that
reported for the only other well-characterized hASNS
inhibitor. The adenylated sulfoximine has a cytostatic
effect on L-asparaginase-resistant MOLT-4 cells cul-
tured in the presence of L-asparaginase, an enzyme
that depletes L-asparagine in the growth medium.
These observations represent direct evidence that
potent hASNS inhibitors may prove to be effective
agents for the clinical treatment of acute lymphoblas-
tic leukemia.
Introduction
The enzyme L-asparaginase (ASNase), which catalyzes
the hydrolysis of L-asparagine [1], is a component of
most therapeutic protocols for the treatment of acute
lymphoblastic leukemia (ALL) [2–4]. The opposing reac-
tion is catalyzed by asparagine synthetase (ASNS),
which converts L-aspartic acid into L-asparagine in a
transformation requiring ATP and a nitrogen source
that is L-glutamine in eukaryotic cells [5]. The human en-
zyme (hASNS) is of clinical interest [6] because several
lines of evidence suggest that the development of
ASNase resistance in ALL is correlated with upregula-
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California 90095-1569.tion and expression of hASNS [7–10]. Although the mo-
lecular basis underlying the therapeutic utility of ASNase
in ALL remains ill defined [6, 9], it is thought that normal
and malignant lymphocytes depend on the uptake of
L-asparagine from circulating plasma for growth [11],
as recently reviewed elsewhere [6]. In turn, this has given
rise to the hypothesis that ASNase exerts its clinical
effects in ALL by depleting L-asparagine in the blood,
with the subsequent efflux of cytoplasmic L-asparagine
from the leukemic blasts [12]. Upregulation of hASNS
activity might overcome such an effect by catalyzing
production of the L-asparagine necessary for cellular
growth when cells are in the presence of ASNase [7].
The clinical significance of this hypothesis has been
challenged, however, by studies in which ASNS concen-
trations and activity were extrapolated from the levels of
mRNA encoding the enzyme [13–15]. New strategies are
therefore needed to probe the molecular mechanisms
by which cellular hASNS contributes to ASNase-
resistant ALL. In particular, cell-permeable compounds
capable of specifically inhibiting the enzyme may be
valuable tools in evaluating whether increased levels
of intracellular asparagine biosynthesis might be the
key change in cellular metabolism that underlies the
appearance of drug resistance. Assays employing
small-molecule libraries to identify potent ASNS inhibi-
tors have not yet been reported, and early studies of
substrate analogs failed to yield any compounds exhib-
iting micromolar affinity against the form of ASNS
present in either murine lymphoblasts and pancreatic
cells [16], or rodent neoplasm leukemia 5178Y/AR cell
lines [17].
Based on the crystal structure of the glutamine-
dependent ASNS from Escherichia coli (AS-B) [18], the
human enzyme is likely built from two domains, each
of which contains a catalytic site. The N-terminal site
catalyzes the conversion of glutamine into glutamic
acid and ammonia, and aspartate is reacted with ATP
in the C-terminal site to yield the reactive intermediate
b-aspartyl-AMP (bAspAMP) (Figure 1), the existence of
which has been demonstrated by isotopic labeling ex-
periments [19, 20]. As is the case in other glutamine-de-
pendent amidotransferases [21], ammonia released in
the N-terminal domain of ASNS travels through an intra-
molecular tunnel linking the active sites, and reacts with
the activated acyladenylate moiety to form asparagine
[6]. Recent kinetic experiments have demonstrated
that bAspAMP is stabilized by the enzyme [22], and we
have shown that stable analogs of this intermediate
are submicromolar inhibitors of ASNS [23]. In this paper,
we describe in vitro experiments showing that the ad-
enylated sulfoximine 1 (Figure 2) [24] is a slow-onset,
tight-binding inhibitor of hASNS. Perhaps more impor-
tantly, we also demonstrate that treatment of a drug-
resistant MOLT-4 cell line [25] with adenylated sulfoxi-
mine 1 has a cytostatic effect. This observation is the
first direct evidence that ASNS inhibitors represent in-
teresting compounds that may prove to be effective
agents for the clinical treatment of ASNase-resistant
ALL, as initially discussed almost 40 years ago [12].
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The Adenylated Methylsulfoximine Moiety
Is a Transition-State Analog
The adenylated sulfoximine 1, as a mixture of diastereo-
isomers 1a and 1b [24] (Figure 2), was first reported as
an inhibitor of the ammonia-dependent variant of
E. coli ASNS (AS-A), an enzyme that has been identified
only in prokaryotes [26] and does not share a common
ancestor with glutamine-dependent ASNS [27]. Based
on the crystal structure of the complex between AS-A
and 1, the adenylated sulfoximine moiety was proposed
to be a stable analog of the transition state for the attack
of ammonia on bAspAMP [24]. In order to verify this
hypothesis, we compared the electrostatic and steric
properties of a model phosphorylated sulfoximine 2
(Figure 3A) and the transition state for the addition of
ammonia to the acylphosphate 3 (Figure 3B) using semi-
empirical calculations [28] at the PM3 level of theory [29].
These calculations also employed a continuum solva-
tion potential [30, 31] so as to model the effects of a po-
larizable medium on the charge distributions in the tran-
sition state and sulfoximine. These studies suggest that
the tetrahedral sulfur atom is a good model for the rehy-
bridized carbonyl carbon in the transition state for am-
monia attack (see Tables S1 and S2 in the Supplemental
Data available with this article online), at least at this rel-
Figure 1. Reactions Catalyzed by ASNS
Ammonia may replace glutamine as a nitrogen source for the
ASNS-catalyzed synthetase reaction.
Figure 2. Chemical Structures of the Adenylated Sulfoximine 1 and
Other Compounds Discussed in the Textatively unsophisticated level of theory. For example, the
S-CH3 bond length in the sulfoximine is 1.77 A˚ compared
to a value of 1.64 A˚ for the analogous C-N bond in the
model transition state, and the related O-S-CH3 and
O-C-N angles in the two structures are 108.2 and
108.7, respectively. There are also interesting steric
and electronic similarities between the methyl substitu-
ent in the phosphorylated sulfoximine moiety and the
ammonia molecule as it undergoes uncatalyzed reaction
with the carbonyl group of the acylphosphate (Tables S2
and S3). Hence, an examination of the electrostatic po-
tential for sulfoximine 2, computed on the electronic iso-
density surface (Figure 3A), shows regions of positive
potential (red) adjacent to the hydrogen substituents.
These presumably result from polarization effects asso-
ciated with the inductive effect of the phosphorylated
sulfoximine moiety, and mimic a similar region of posi-
tive potential about the ammonia hydrogens that is
seen when the electrostatic potential at the isodensity
surface of the model transition state 3 is visualized
(Figure 3B).
In Vitro Characterization of 1 as an Inhibitor
of Human ASNS
We initially assayed the ability of the adenylated sulfox-
imine 1 (as a mixture of diastereoisomers 1a and 1b) to
inhibit the ammonia-dependent activity of a C-terminally
tagged form of glutamine-dependent hASNS expressed
in Sf9 cells [32]. By using a coupled assay to detect inor-
ganic pyrophosphate (PPi) [33], which is formed in a 1:1
stoichiometry with asparagine by the human enzyme
[34], time-dependent inhibition was observed when re-
actions were initiated by the addition of hASNS to a mix-
ture of substrates containing the transition-state analog
(Figure 4A). Control experiments established that the
sulfoximine did not affect the PPi detection assay (data
not shown), but it was possible that the presence of 1
had decoupled asparagine and PPi formation. The
Figure 3. Computational Evaluation of the Adenylated Methylsul-
foximine Moiety as a Stable Analog of the Transition State for
Asparagine Formation
(A) Structure of the model sulfoximine 2 (left), and graphical repre-
sentations of the PM3-optimized molecular structure (middle) and
electrostatic properties (right) of this compound.
(B) Structure of the transition state for the attack of ammonia on the
model acylphosphate 3 (left), and graphical representations of the
PM3-optimized molecular structure (middle) and electrostatic
properties (right) of this transition state. Dotted lines represent
weak interactions, and the electrostatic potential is mapped on
the isodensity surface in both figures.
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end-point assay in which recombinant ASNS was incu-
bated with substrates at various sulfoximine concentra-
tions before reaction was terminated by the addition of
trichloroacetic acid. The resulting solution was then
assayed for PPi [33], and the asparagine formed was
quantitated by HPLC after conversion into its 2,4-dini-
trophenol derivative [22]. The results show that the
product stoichiometry was not significantly affected by
the inhibitor, at least within the experimental error (see
Figure S1).
In previous studies of the ability of 1 to inhibit the AS-
B, it was reported that the adenylated sulfoximine did
not bind to the free enzyme [35]. We therefore examined
whether this was the case for its interaction with hASNS
by measuring the residual activity of the human enzyme
after incubation with 1 for 10 min and subsequent filtra-
tion through a Sephadex G-50 spin column. These ex-
periments showed that ASNS synthetase activity was
reduced by incubation with the adenylated sulfoximine
in a concentration-dependent manner (Table S1), sug-
gesting that the inhibitor was capable of binding to the
free enzyme. This contrasts with its observed kinetic be-
havior with AS-B under similar reaction conditions, and
in the absence of a crystal structure for hASNS, it is dif-
Figure 4. Steady-State Kinetic Behavior of hASNS in the Presence
of the Adenylated Sulfoximine 1
(A) Progress curves showing PPi formation as a function of incuba-
tion time for ammonia-dependent synthetase activity at various
concentrations of 1: open circles, 0 mM; closed circles, 1 mM;
open squares, 2 mM; closed squares, 4 mM; open diamonds,
6 mM; closed diamonds, 10 mM. Lines represent the fit used to ob-
tain the kinetic parameters for inhibition.
(B) Kinetic model used in the quantitative analysis of the steady-
state progress curves. E, enzyme; I, inhibitor.
(C) Reactivation of inhibited hASNS as a function of time. The line
shows the exponential of best fit to the data.
(D) Progress curves showing PPi formation as a function of incuba-
tion time for glutamine-dependent synthetase activity at various
concentrations of 1: open circles, 0 mM; closed circles, 1 mM;
open squares, 2 mM; closed squares, 4 mM; open diamonds,
6 mM; closed diamonds, 10 mM. Lines represent the fit used to ob-
tain the kinetic parameters for inhibition.ficult to assess the structural basis for this apparent
difference in inhibition kinetics. Given the multidomain
structure of the two glutamine-dependent enzymes, it
is possible that differences in the conformational states
of the two forms of ASNS may result in modified acces-
sibility of the adenylated sulfoximine to its binding site.
The fact that 1 could bind to free hASNS, however, per-
mitted quantitative analysis of the progress-curve data
for the ammonia-dependent reaction using a standard
kinetic model for slow-onset, tight-binding inhibition
(Figure 4B) [36]. Curve fitting gave values of 280 6 43
nM and 2.56 0.3 nM for KI and KI*, respectively (Table 1).
This value of KI* is 100-fold smaller than that observed
for the inhibition of hASNS by the N-acylsulfonamide 4
(Figure 2A), which is an analog of bAspAMP [23], and
compares very favorably to the KI* value of 67 nM
reported for the interaction of the diastereoisomeric
mixture 1a and 1b with the bacterial, ammonia-depen-
dent AS-A [24].
Of course, this analysis makes the assumption that
only one of the two diastereoisomers (1a or 1b) is
capable of undergoing a tight-binding interaction with
hASNS. Evidence to support this assertion is provided
by previous studies showing the stereochemical
dependence of tight-binding inhibition by sulfoximine
derivatives [37–39]. Hence, in all situations to date for
which diastereoisomeric and enantiomeric mixtures of
sulfoximine-based inhibitors have been separated,
only one of these structures has exhibited tight binding
inhibition, with the others in the mixture generally exhib-
iting no activity. This behavior seems reasonable given
that active sites generally stabilize one of the two stereo-
chemically distinct transition states for nucleophilic
attack on activated carbonyl groups due to the location
of the single oxyanion ‘‘hole’’ [40]. On the other hand, we
did consider the situation in which one of the diastereo-
isomeric adenylated sulfoximines acted as a reversible
inhibitor. In this situation, because the concentrations
of 1a and 1b in the mixture are identical, the integrated
rate expression for time-dependent product formation
can be written as:
P = vsst + ½12 expð2 ktÞ$½vo2 vss=k; (1)
where k takes the following form [41]:
k = k6 + k5ðI=KiÞ=½1 + A=Ka + I=2Kif1 + Ki=Kxg; (2)
and Ki and KX are the reversible inhibition constants for
the tight-binding and reversible inhibitors, respectively,
and I is the total concentration of adenylated sulfoximine
1. From this equation, in situations where KX is signifi-
cantly greater than Ki, the effects of the other diastereo-
isomer are unlikely to have a significant impact on the
Table 1. Steady-State Parameters for Inhibition of Human ASNS
by the Adenylated Sulfoximine 1
Nitrogen
Source
KI
(nM) k5 (s
21) k6 (s
21)
kobs/[I]tot
(M21 s21)
K*I
(nM)
NH4Cl 285 2.98 3 10
23 2.6 3 1025 436 2.46
L-Glutamine 985 2.81 3 1023 7.1 3 1025 219 24.3
Parameters are those obtained by fitting to a kinetic model in which
the inhibitor binds to free enzyme, and assuming a Ka value for ATP
of 0.2 mM. See text for full details of experimental conditions.
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Equation 2 with various values of KX did not improve our
ability to fit the experimental progress curves.
We next evaluated the reversibility of in vitro hASNS
inhibition using standard protocols [42]. Thus, after
complete inactivation of the enzyme by incubating
hASNS with ATP, aspartate, and ammonium chloride in
the presence of the adenylated sulfoximine 1 (as judged
by the cessation of PPi production), the reaction mixture
was subjected to gel filtration on a Sephadex G-50
column. Fractions containing hASNS were diluted into
a solution containing substrates at saturating concen-
tration, and PPi formation was monitored spectroscop-
ically over a period of several hours (Figure 4C). Over
the time course of the experiment, the inactivated sam-
ple of human ASNS regained 56% of its activity relative
to a control sample of the enzyme that had been sub-
jected to identical treatment in the absence of sulfoxi-
mine 1, and quantitative analysis gave a value of 7.4 hr
for the half-life of reactivation, which is consistent with
the estimate of k6 obtained from analysis of progress-
curve data (Table 1). The demonstrated reversibility of
hASNS inhibition again contrasts with reported observa-
tions on the bacterial enzymes, given that both AS-A and
AS-B do not regain activity after being inactivated by the
adenylated sulfoximine 1 [24, 35].
Given the relatively complicated structure of the ad-
enylated sulfoximine 1, we also examined whether
hASNS was capable of catalyzing the adenylation of
the structurally much simpler methylsulfoximine 5 (Fig-
ure 2), which is easily prepared as a mixture of diastereo-
isomers 5a and 5b from L-S-methylcysteine, and is an
intermediate in the synthesis of 1 [24]. These experi-
ments were prompted by the observation that the methi-
onine sulfoximine 6 (Figure 2) [43] binds to the metabol-
ically important enzyme, glutamine synthetase (GS) [44,
45], where it undergoes enzyme-catalyzed phosphoryla-
tion in the presence of ATP to yield the phosphorylated
derivative 7 [46]. The latter compound is a potent GS in-
hibitor because it resembles the transition state formed
when ammonia attacks the g-glutamylphosphate inter-
mediate 8 (Figure 2) [47]. Despite testing a variety of con-
ditions, hASNS was not inhibited by the sulfoximine 5 in
the presence of ATP, suggesting that the enzyme did not
catalyze formation of the adenylated sulfoximine 1 (data
not shown), and showing the importance of the adenylyl
moiety for ASNS inhibition. On the basis of these obser-
vations, it is possible that 1 was exerting its effects by
covalently modifying the enzyme. We therefore carried
out a series of experiments to evaluate whether protein
adenylation was indeed occurring when hASNS was in-
cubated with 1 by using conditions that we had devel-
oped for employing electrospray time-of-flight (TOF)
mass spectrometry to observe tryptic peptides from
over 90% of the sequence of recombinant hASNS [32].
We incubated the enzyme with the adenylated sulfoxi-
mine 1 (10 mM) until the rate of pyrophosphate produc-
tion became zero, and the protein was then subjected
to in-gel digestion with trypsin under our standard con-
ditions [32]. Mass spectrometric analysis of the peptide
fragments from the sample of fully inhibited hASNS
showed no fragments with an increased mass corre-
sponding to that expected if adenylation of any protein
side chains had taken place (data not shown). In thisregard, we note that all peptides containing residues
that are located in the synthetase active site of the en-
zyme can be observed using electrospray TOF mass
spectrometry [32].
Given that L-glutamine is the likely physiological nitro-
gen source for asparagine biosynthesis in eukaryotic
cells [6], we also investigated the ability of 1 to inhibit
the glutamine-dependent synthetase activity of hASNS
at a physiologically relevant ATP concentration (5 mM)
and pH 8 (Figure 4D). Once again, slow-onset tight-bind-
ing inhibition was observed, and the quantitative analy-
sis of the progress curves for PPi production yielded
values of 1000 6 176 nM and 24 6 2.8 nM for KI and
KI*, respectively, under these conditions (Table 1). The
10-fold decrease in the ability of 1 to inhibit the gluta-
mine-dependent synthetase reaction may arise from
conformational differences in the C-terminal domain of
the human enzymes that are associated with occupancy
of the N-terminal glutaminase site by substrate, L-gluta-
mate, or the thioester intermediate [48, 49]. We therefore
evaluated the effects of the adenylated sulfoximine 1 on
the glutaminase activity of the enzyme, hASNS, with a
continuous assay in which glutamate formed by
ASNS-catalyzed glutamine hydrolysis is coupled to the
production of NADH [50]. The rationale for these exper-
iments came from previous studies showing that the
presence of ATP stimulates the glutaminase activity of
E. coli AS-B [51]; an effect that was used to demonstrate
the functional roles of conserved residues in the N-ter-
minal, glutaminase domain [52]. In the presence of 10
mM adenylated sulfoximine 1, kcat/Km for the glutamin-
ase activity of hASNS was 982 M21 s21, which was rela-
tively unchanged from the value of 795 M21 s21 deter-
mined for the reaction in the absence of the inhibitor
(Figure 5). This finding was unexpected, however, on
the basis of ATP-dependent stimulation of the glutamin-
ase activity of AS-B [51], and so we assayed whether the
glutaminase activity of hASNS was affected by ATP.
Figure 5. Effect of the Adenylated Sulfoximine 1 on the Steady-
State Glutaminase Activity of hASNS
Glutamine dependence of the glutaminase activity in the presence
(closed circles) and absence (open circles) of 10 mM 1. Lines repre-
sent the fit to the Michaelis-Menten equations used to obtain the
steady-state kinetic parameters.
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ATP had almost no impact on kcat/Km for the glutamin-
ase activity of hASNS, which was determined to be
674 M21 s21. The lack of effect on the steady-state
rate of ASNS-catalyzed glutamine hydrolysis for either
ATP or the sulfoximine derivative 1 contrasts with the
stimulation of glutaminase activity observed for other
members of the class II glutamine-dependent amido-
transferase family [53, 54], including glutamine 50-phos-
phoribosyl-pyrophosphate amidotransferase [55] and
glutamine fructose-6-phosphate amidotransferase [56],
when nitrogen-accepting substrates are bound in the
C-terminal synthetase domains of these enzymes.
Given the ability of the adenylated sulfoximine 1 to
stimulate the glutaminase activity of free hASNS, we ex-
amined whether this remained the case under condi-
tions in which ATP and L-aspartate were present. In
these experiments, we examined the Asn:Glu ratio after
20 min incubation in the presence and absence of 1
with our standard HPLC-based end-point assay [22]
(Figure S2). The results showed that 10 mM 1 did
increase the Asn:Glu ratio for hASNS under these condi-
tions from 1:1.3 to 1:2.4, presumably because the
enzyme continues to catalyze the hydrolysis of the glu-
tamine amide even when the adenylated sulfoximine is
bound in the synthetase active site.
Characterization of the Effects of the ASNS on the
Proliferation of an Asparaginase-Resistant MOLT-4
Cell Line
After demonstrating that the adenylated sulfoximine 1 is
the first ASNS inhibitor with low-nanomolar affinity for
the enzyme, the effects of incubating this compound
with a MOLT-4 leukemia cell line [25] were investigated.
The MOLT-4(R) cell line used for these experiments is
continuously maintained by us in the presence of 1 U/mg
ASNase [7, 57], and has been used extensively in
previous studies of molecular mechanisms mediating
ASNase resistance [6, 7, 57, 58]. The MOLT-4(R) cells
were transferred to medium containing the hASNS inhib-
itor 1 at concentrations of 0.1–1 mM. These high con-
centrations were chosen because we anticipated that
the charged functional groups on the molecule, which
are known to be important in mediating recognition
[23], would negatively impact cell permeability. Incuba-
tions were performed for a total of 48 hr, and the effect
of the ASNS inhibitor on cell proliferation was assayed
using a dye-based (WST-1) method [59] for estimating
the number of MOLT-4 cells. The adenylated sulfoximine
1 inhibited, in a concentration-dependent manner, the
ability of the MOLT-4(R) cells to proliferate. Interestingly,
this cytostatic effect was accentuated by the simulta-
neous presence of ASNase in the growth medium
(Figure 6). The origin of this synergistic effect remains
to be determined. One possible explanation is that the
greater degree of cytostatic action in the presence of
the ASNase is a consequence of the inhibitor being
poorly transported into the MOLT-4(R) cells, thereby
preventing complete inhibition of asparagine biosynthe-
sis. As a result, any simultaneous depletion of pre-exist-
ing asparagine by cotreatment of the cells with ASNase
is more effective than using the inhibitor alone. In light
of finding that the ASNS-sulfoximine complex retains
its ability to catalyze glutamine hydrolysis, alternativemechanisms in which the cellular regulation of gluta-
mine-dependent metabolism is perturbed may also un-
derlie the observed synergy of ASNase and the hASNS
inhibitor.
Significance
ASNS is a structurally and mechanistically complex
enzyme [2] that likely contributes to cellular mecha-
nisms mediating ASNase resistance in ALL [6].
Despite considerable research activity aimed at delin-
eating whether upregulation of ASNS expression is a
direct cause of ASNase resistance in patients [14,
60], this question remains unresolved, in part because
of the absence of potent, and selective, ASNS inhibi-
tors that prevent intracellular asparagine biosynthe-
sis. In this paper, we describe a transition state analog
that inhibits hASNS with nanomolar activity in vitro,
and confirm that the adenylated sulfoximine 1 is a
slow-onset, tight-binding inhibitor even when ATP is
present at physiological concentration. Although the
affinity of hASNS for sulfoximine 1 is dependent on
the nitrogen source used by the enzyme, the revers-
ibility of inhibition suggests that 1 forms complemen-
tary noncovalent interactions, presumably with resi-
dues located in the C-terminal synthetase active site.
More importantly, the adenylated sulfoximine 1 slows
the growth of ASNase-resistant MOLT-4 cells in the
presence of ASNase. These experiments appear to
be the first direct validation of the long-held hypothe-
sis that hASNS inhibitors represent potential thera-
peutic agents for the treatment of ALL and related leu-
kemias. On the other hand, more studies need to be
performed that address (1) the nature of the molecular
events in the cell underpinning the synergistic interac-
tion of the adenylated sulfoximine 1 and ASNase, and
(2) whether other leukemia cell lines and primary
ALL cells will show similar behavior on treatment
with 1 and/or more cell-permeable analogs. Our obser-
vations demonstrate the feasibility of employing
methylsulfoximine derivatives as ‘‘lead’’ structures in
future efforts to obtain potent, small-molecule hASNS
Figure 6. Effect of the Adenylated Sulfoximine 1 on MOLT-4 Prolif-
eration in the Presence and Absence of 1 U ASNase
Note that cell proliferation is defined as the number of viable cells
after 48 hr expressed as the ratio to the initial number of cells (t =
0). Error bars represent the standard deviation of triplicate experi-
ments.
Chemistry & Biology
1344inhibitors [61]. Such compounds not only have poten-
tial therapeutic value, but also represent new tools that
can be used in modern profiling strategies [62, 63] for
delineating the role of ASNS expression in ASNase
resistance.
Experimental Procedures
Materials
All samples of the adenylated sulfoximine 1 (as a 1:1 mixture of dia-
stereoisomers 1a and 1b) and the methylsulfoximine 5 (as a 1:1 mix-
ture of diastereoisomers 5a and 5b) were obtained by chemical syn-
thesis following procedures in the literature [24]. Unless otherwise
stated, all other chemicals and reagents, including authentic sam-
ples of dinitrobenzene derivatives of L-asparagine, L-aspartate,
and L-glutamate, were purchased from Sigma-Aldrich (St. Louis,
MO), and were of the highest available purity. Protein concentrations
were determined by a modified Bradford assay (Pierce, Rockford, IL)
based on standard curves constructed using bovine serum albumin
[64]. L-glutamine was purified by recrystallization prior to use in all
assays containing this reagent. Caution: extreme care should be
taken when handling solutions of 2,4-dinitrofluorobenzene (DNFB)
in organic solvents, because this reagent is a potent allergen and
will penetrate many types of laboratory gloves [65].
Expression and Purification of Recombinant, C-Terminally
Tagged ASNS
Multimilligram amounts of wild-type, C-terminally tagged human
ASNS were expressed in Sf9 cells and purified using procedures
that have been reported elsewhere [32].
Steady-State Kinetic Assays and Data Analysis
Progress curves were obtained under steady-state conditions using
a continuous assay in which the formation of PPi is measured by
monitoring the consumption of NADH (340 nm) (Sigma Technical
Bulletin BI-100). It has been shown that the asparagine and PPi are
produced in a 1:1 ratio by the recombinant, C-terminally tagged
form of hASNS [32]. In these experiments, purified hASNS (2 mg)
was incubated at 37C with substrates in 100 mM EPPS buffer (pH
8), containing 5 mM ATP, 10 mM MgCl2, 100 mM NH4Cl, 10 mM L-
aspartic acid, and varying concentrations of the adenylated sulfox-
imine 1 (0–10 mM) over a period of 20 min (1 ml final volume). Reac-
tions were initiated by addition of the enzyme. The resulting
progress curves were analyzed by fitting the data to Equation 1
[36] using the Kaleidagraph v3.5 software package (Synergy, Read-
ing, PA), where P is the PPi concentration (equivalent to the amount
of asparagine) formed at time t, vo and vss are initial and steady-state
velocities, respectively, and k is the apparent first-order rate con-
stant for isomerization of EI to EI*. The values of k at different inhib-
itor concentrations were therefore determined by fitting, and used to
find k6 from the expression:
k6 = k$vss=vo: (3)
The average value of k6 could then be computed, and this was
subsequently used to obtain estimates of Ki and k5 by fitting to the
following equation:
k = k6 + k5$½ð½I=KiÞ=ð1 + ½ATP=Ka + ½I=KiÞ; (4)
where [I] is the concentration of the adenylated sulfoximine, [ATP] =
5 mM, and Ka was taken to be 0.2 mM [23]. For experiments in which
L-glutamine replaced ammonia as the nitrogen source, purified
hASNS (2 mg) was incubated at 37C in EPPS buffer (pH 8, 1 ml final
volume), containing 5 mM ATP, 10 mM MgCl2, 25 mM L-glutamine,
10 mM L-aspartic acid, and varying concentrations of 1 (0–10 mM)
over a period of 20 min. Control experiments using known amounts
of PPi demonstrated that the assay reagent was not affected by the
presence of the adenylated sulfoximine 1.
In order to check that the inhibitor 1 did not affect the 1:1 stoichi-
ometry of Asn:PPi, an alternate HPLC-based assay [22] was em-
ployed in control experiments to measure the amount of L-aspara-
gine directly. Thus, recombinant hASNS (4 mg) was incubated at
37C with 5 mM ATP, 10 mM L-aspartic acid, 10 mM MgCl2, and100 mM NH4Cl in 100 mM EPPS buffer (pH 8), and varying concen-
trations of the adenylated sulfoximine 1 (0, 2, or 10 mM) over a period
of 20 min (1 ml final volume). Reactions were initiated by addition of
the enzyme. After quenching with glacial AcOH, and neutralization
with aq. NaOH, an aliquot of each mixture (40 ml) was diluted (200
ml final volume) with 400 mM aq. Na2CO3 (pH 9), containing 10%
DMSO and 30% DNFB (as a saturated solution in EtOH). The result-
ing solutions were heated at 50C for 45 min to permit reaction of
DNFB with the amino acids to yield their dinitrophenyl (DNP) deriva-
tives [66, 67]. Aliquots of each assay mixture (10 ml) were analyzed by
reverse-phase HPLC (RP-HPLC) using a C18 column (Varian Inc.,
Palo Alto, CA). The DNP-derivatized amino acids were eluted with
a step gradient of 40 mM formic acid buffer (pH 3.6), and CH3CN.
In this procedure, the initial concentration of the organic phase
(CH3CN) was 13.5%, which was increased to 14.5% over a period
of 21 min. After this time, the amount of CH3CN was increased to
80% over a period of 30 s, and elution continued for a further 20
min. Eluted amino acid DNFB derivatives were monitored at 365
nm and identified by comparison to authentic standards. Under
these conditions, DNP-asparagine exhibited a retention time of ap-
proximately 21 min, and could be quantified on the basis of its peak
area. Calibration curves were constructed using solutions of pure L-
asparagine derivatized in the same manner as the samples. The
amount of asparagine detected in this assay was compared to PPi
as determined by the coupled enzyme assay (Sigma). These exper-
iments were also repeated for mixtures containing 0.5 mM ATP.
The glutaminase activity of hASNS was assayed by determining L-
glutamate formation with glutamate dehydrogenase in the presence
of NAD+ [50]. Assay mixtures (200 ml total volume) contained varying
concentrations of L-glutamine (1–50 mM) and 8 mM MgCl2 in 100
mM EPPS buffer (pH 8), containing 0.5 mM DTT and 100 mM NaCl,
and reaction was initiated by the addition of recombinant hASNS
(2.6 mg). The resulting solution was then incubated at 37C for 20
min before being terminated by addition of 20% trichloroacetic
acid (30 ml). The mixture was added to 770 ml of the coupling reagent
(300 mM glycine, 250 mM hydrazine (pH 9), containing 1 mM ADP,
1.6 mM NAD+, and 2.2 U glutamate dehydrogenase) and incubated
for 30 min (1 ml final volume). The absorbance at 340 nm of the re-
sulting solution was measured, and the amount of L-glutamate de-
termined from a standard curve. Steady-state parameters were ob-
tained by fitting the data to the Michaelis-Menten equation [68] using
the Kaleidagraph v3.5 software package. These experiments were
repeated in the presence of ATP (5 mM) or the adenylated sulfoxi-
mine 1 (10 mM).
Enzyme Binding Assay
Purified hASNS (4 mg) was incubated in the presence (5 mM or 10 mM)
or absence of the adenylated sulfoximine 1 for 10 min in 100 mM
EPPS (pH 8, 20 ml total volume). The resulting reaction mixtures
were then loaded onto a Sephadex G-50 spin column and washed
with 100 ml EPPS buffer (100 mM, pH 8). The activity of the enzyme
and its concentration in each of the three solutions was determined
using the coupled assay for detection of PPi and the modified Brad-
ford assay, respectively. Experiments to monitor the synthetase ac-
tivity employed saturating levels of ATP and L-aspartic acid, 10 mM
MgCl2, and 100 mM NH4Cl, and PPi production was measured over
a 20 min period.
Enzyme Reactivation Assay
Recombinant, wild-type hAS (at a final concentration of 0.25 mM)
was added to a solution of 5 mM sulfoximine 1, 0.5 mM ATP, 10
mM MgCl2, 10 mM Asp, and 100 mM NH4Cl in 100 mM EPPS (pH
8, 1 ml total volume). The solution was incubated until synthetase ac-
tivity ceased, as measured by PPi production [33]. The reaction mix-
ture was then filtered through a Sephadex G-25 column using elution
with 100 mM EPPS (pH 8), so as to remove substrates, products, and
the unbound sulfoximine 1. The reactivation of AS activity was then
monitored by measuring ammonia-dependent asparagine formation
in aliquots (500 ml) of the fractions containing human ASNS, which
were diluted 20-fold into assay mixtures containing 5 mM ATP, 10
mM MgCl2, 10 mM aspartate, and 100 mM NH4Cl in 100 mM EPPS
buffer (pH 8) at 37C.
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Recombinant, wild-type hASNS (at a final concentration of 0.25 mM)
was added to a solution of 5 mM sulfoximine 1, 5 mM ATP, 10 mM
MgCl2, 10 mM Asp, and 100 mM NH4Cl in 100 mM EPPS, (pH 8, 1
ml total volume). The solution was incubated until synthetase activ-
ity ceased, as measured by PPi production [33]. The resulting protein
was isolated and a sample purified by SDS-PAGE on a 9% resolving
gel at 110 V, including a lane for molecular weight markers. Staining
with Coomassie brilliant blue dye revealed a protein band of 66 kDa
molecular weight, which was excised and destained by soaking the
gel pieces in 50% methanol (1 ml) overnight, followed by several ad-
ditional washings. Cysteine residues were reduced with dithiothrei-
tol and alkylated with iodoacetamide to give the carbamidomethy-
lated-modified protein, which was then digested in-gel with trypsin
(625 ng trypsin per gel band) on ice for 45 min and overnight at
37C. The trypsin solution was replaced with 20 mM ammonium bi-
carbonate, and the reaction quenched with 5 ml glacial AcOH. After
centrifugation, the sample was desalted prior to mass spectrometric
analysis by elution through C18 ZipTips (Millipore, Billerica, MA) with
a solution of 50% aq. CH3CN containing 1% HCO2H.
The separation of tryptic peptides produced in the protein digest
was performed by capillary RP-HPLC on a 15 cm 3 75 mm i.d. Pep-
Map C18 column (LC Packings, San Francisco, CA) in combination
with an Ultimate Capillary HPLC System (LC Packings) operating
at a flow rate of 200 nl/min. Inline mass spectrometric analysis of
the column eluate was accomplished with a hybrid TOF instrument
(QSTAR; Applied Biosystems, Foster City, CA) equipped with
a nano-electrospray source. Fragment ion data obtained on the
TOF instrument were searched against the NCBI nr sequence data-
base using the Mascot database search engine (Matrix Science,
Boston, MA). Peptide masses were calculated based on the mono-
isotopic peak and charge state of each ion cluster, and compared to
those expected for tryptic peptides, and their corresponding adeny-
lated derivatives, from recombinant hASNS. Probability-based
MOWSE scores above the default significant value were considered
for peptide identification in addition to validation by manual interpre-
tation of tandem MS/MS data. Control experiments employed
hASNS treated in an identical manner, except that the adenylated
sulfoximine 1 was absent from the initial incubation mixture.
Cell-Based Assays
The effect of the adenylated sulfoximine 1 was tested on cell prolif-
eration by first seeding MOLT-4/R-resistant cells into 96-well plates
at a density of 4000 cells per well with RPMI 1640 medium with 10%
FBS, and incubated in 95% air with 5% CO2 at 37
C. MOLT-4/R is
a derivative of a human ALL cell line (MOLT-4) [25] that is resistant
to the presence of ASNase in the medium and shows upregulated
levels of ASNS expression [7, 57]. The sulfoximine 1 was diluted to
give 0.1, 0.5, and 1.0 mM concentrations in culture medium, and
cells were incubated with the compound in the presence or absence
of 1 U ASNase. Cell viability was determined 48 hr after treatment by
the WST-1 Cell Proliferation Assay (Roche Diagnostics, Indianapo-
lis, IN). The optical density was read at 450 and 690 nm by an
ELX800 Universal Microplate Reader (Bio-Tek Instruments, Inc., Wi-
nooski, VT). The mean cell titer of treated samples relative to control
cells prior to treatment (time = 0) was calculated, and the data ex-
pressed as the mean 6 SD of triplicate experiments.
Molecular Modeling Studies
All model structures were built using the graphical interface of the
BioMedCAChe V6.5 software package (Fujitsu America Inc., Beaver-
ton, OR), and their geometries were optimized using the PM3 semi-
empirical model chemistry [29] in combination with the COSMO con-
tinuum solvation potential [30] as implemented in MOPAC V7.0
(Fujitsu America Inc.). The transition state for ammonia attack on
the acetylphosphate derivative was obtained using standard
methods (IRC option) [69], and all electrostatic potentials were cal-
culated and visually displayed using algorithms implemented within
BioMedCAChe V6.5 [70].
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